Samsung is backing Alzheimer’s disease blood test developer C2N Diagnostics, with $10 million to help scale up its commercial work and R&D pipeline. The conglomerate’s investment—which collectively ...
Dr. Joel Braunstein, CEO of C2N, says, “Samsung is an international leader and widely recognized for the seriousness and thorough reviews it undertakes in its strategic decisions. We greatly ...
It might not be the world’s most exciting update, but disappointing battery life was one of our biggest issues with the Galaxy Watch 5. It might not be the world’s most exciting update, but ...
Samsung Electronics’ medical device division showed off a selection of new artificial intelligence-based imaging tools yesterday at the Radiological Society of North America’s 2018 Annual Meeting in ...
Samsung will feature the latest innovation in cutting-edge mobile computed tomography, including the state-of-the-art OmniTom Elite with Photon Counting Detector (PCD) technology DANVERS, ...
GRAIL's financial position is reinforced by $435 million in new funding, including strategic backing from Samsung for ...
Presenting advanced image technology and clinical studies at Satellite Symposia VIENNA, March 2, 2017 /PRNewswire/ -- To empower radiologists around the world, Samsung Electronics Co., Ltd. is ...
The Chosun Ilbo on MSN
Samsung Invests $110M in GRAIL for Early Blood Cancer Detection
Samsung Electronics and Samsung C&T announced on the 16th, local time, that they will invest $110 million (approximately 155 ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A St. Louis-based company known ...
GRAIL exhibits strong revenue momentum, achieving an average annual growth rate of 22.4% over the past three years versus 5.4 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback